Cargando…

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies

Haematological malignancies are heterogeneous groups of cancers of the bone marrow, blood or lymph nodes, and while therapeutic advances have greatly improved the lifespan and quality of life of those afflicted, many of these cancers remain incurable. The iron-dependent, lipid oxidation-mediated for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mynott, Rachel L., Habib, Ali, Best, Oliver G., Wallington-Gates, Craig T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146166/ https://www.ncbi.nlm.nih.gov/pubmed/37108836 http://dx.doi.org/10.3390/ijms24087661

Ejemplares similares

Prognostic and predictive biomarker developments in multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2021)

Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2018)

Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2021)

Tuberculosis in Patients with Haematological Malignancies
por: Anibarro, Luis, et al.
Publicado: (2014)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Cancer stem cells in haematological malignancies
por: Zagozdzon, Radoslaw, et al.
Publicado: (2015)

The hypoxia signalling pathway in haematological malignancies
por: Irigoyen, Marta, et al.
Publicado: (2017)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

Targeting hypoxia in solid and haematological malignancies
por: Harris, Bill, et al.
Publicado: (2022)

The Role of miRNA in Haematological Malignancy
por: Gounaris-Shannon, Stephanie, et al.
Publicado: (2013)

Breast imaging findings in haematological malignancies
por: Glazebrook, K. N., et al.
Publicado: (2014)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Long Non-Coding RNAs in Haematological Malignancies
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2013)

Components of the Lectin Pathway of Complement in Haematologic Malignancies
por: Cedzyński, Maciej, et al.
Publicado: (2020)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Skelding, Kathryn A., et al.
Publicado: (2021)

Beta-D-Glucan in Patients with Haematological Malignancies
por: Mikulska, Malgorzata, et al.
Publicado: (2021)

Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013)

Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
por: Banerji, Versha, et al.
Publicado: (2012)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Nanotechnology-based antiviral therapeutics
por: Chakravarty, Malobika, et al.
Publicado: (2020)

Early integration of palliative care for patients with haematological malignancies
por: Shaulov, Adir, et al.
Publicado: (2022)

Nanotechnology Innovations to Enhance the Therapeutic Efficacy of Quercetin
por: Pinheiro, Rúben G. R., et al.
Publicado: (2021)

Scope of nanotechnology in ovarian cancer therapeutics
por: Yallapu, Murali M, et al.
Publicado: (2010)

Delivery of Cancer Therapeutics Using Nanotechnology
por: Lim, Eun-Kyung, et al.
Publicado: (2013)

PSYCHOLOGICAL ASPECTS OF HAEMATOLOGICAL MALIGNANCIES
por: Kulhara, P., et al.
Publicado: (1990)

Invasive Fungal Infections in Children with Haematological Malignancies: Diagnostic and Therapeutic Challenges
por: Tragiannidis, Athanasios, et al.
Publicado: (2021)

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
por: Smith, A, et al.
Publicado: (2011)

Expression of testicular genes in haematological malignancies
por: Lim, S H, et al.
Publicado: (1999)

COVID-19 in children with haematological malignancies
por: Millen, Gerard Cathal, et al.
Publicado: (2022)

Improving TCR Gene Therapy for Treatment of Haematological Malignancies
por: Nicholson, Emma, et al.
Publicado: (2012)

Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies
por: Parmesar, Kevon, et al.
Publicado: (2016)

Preferred and actual place of death in haematological malignancies: a report from the UK haematological malignancy research network
por: Sheridan, Rebecca, et al.
Publicado: (2021)

Roles of ferroptosis in urologic malignancies
por: Zhao, Shankun, et al.
Publicado: (2021)

Precision-based exercise as a new therapeutic option for children and adolescents with haematological malignancies
por: Lanfranconi, Francesca, et al.
Publicado: (2020)

Haematological malignancies implications during the times of the COVID-19 pandemic
por: Papakonstantinou, Eleni, et al.
Publicado: (2021)

Transient Receptor Potential (TRP) Channels in Haematological Malignancies: An Update
por: Maggi, Federica, et al.
Publicado: (2021)

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
por: Mrozik, Krzysztof Marek, et al.
Publicado: (2018)

Production and therapeutic use of astaxanthin in the nanotechnology era
por: Abdelazim, Karim, et al.
Publicado: (2023)

Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations
por: Gliszczyńska, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m1usph8sdk9iefqnujrkd23v2e